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Background: Stress-induced hyperglycemia is common in critically ill patients. A few
forms of model-based glycemic control have been introduced to reduce this phenomena
and among them is the automated STAR protocol which has been used in the Christchurch
and Gyulá hospitals' intensive care units (ICUs) since 2010.
Methods: This article presents the pilot trial assessment of STAR protocol which has been
implemented in the International Islamic University Malaysia Medical Centre (IIUMMC)
Hospital ICU since December 2017. One hundred and forty-two patients who received STAR
treatment for more than 20 hours were used in the assessment. The initial results are
presented to discuss the ability to adopt and adapt the model-based control framework in a
Malaysian environment by analyzing its performance and safety.
Results: Overall, 60.7% of blood glucose measurements were in the target band. Only
0.78% and 0.02% of cohort measurements were below 4.0 mmol/L and 2.2 mmol/L (the
limitsfor mild and severe hypoglycemia, respectively). Treatment preference-wise, the clin-
ical staff were favorable of longer intervention options when available. However, 1 hourly
treatments were still used in 73.7% of cases.
Conclusion: The protocol succeeded in achieving patient-speciﬁc glycemic control while
maintaining safety and was trusted by nurses to reduce workload. Its lower performance
results, however, give the indication for modiﬁcation in some of the control settings to better
ﬁt the Malaysian environment.
Keywords: glycemic control, intensive care unit, model-based control, pilot trial, Malaysian
hospital
Introduction
Stress-induced hyperglycemia is common in critically ill patients, even among those
without diabetes mellitus.1–4 Themetabolic response to stress is characterized by major
changes in glycemia metabolism. Current research suggests that hyperglycemia is not
only a marker for severity of illness, it also worsens outcomes, leading to an increased
risk of further complications, such as severe infection,5 myocardial infarction,6 poly-
neuropathy, and multiple-organ failure.3 Glycemic control (GC) has been shown to
reduce Intensive Care Unit (ICU) patient mortality up to 45%.3,7–9 However, some
subsequent studies failed to repeat these results, and resulted in a higher incidence of
hypoglycemia if compared to conventional insulin control.10–12 One of the concerns
that can be extracted from the above studies is the need to be cognizant in deﬁning the
“sweet spot” between tight control and conventional care.
Another identiﬁed issue with existing GC approaches is their inability to
identify patient-speciﬁc dynamics, thus limiting their ability to provide consistent,
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safe, and effective GC. A recent study by Uyttendaele et
al13 suggested that the association between hyperglycemia
and outcome is determined by the quality of GC, rather
than by the underlying patient condition. A patient-speciﬁc
approach is required to successfully manage signiﬁcant
inter- and intra-patient variability.14 In this context,
model-based controllers using mathematical models of
patient physiology can be applied to capture patient-spe-
ciﬁc response to optimize insulin and nutrition inputs.15
The ability to provide safe and effective control across
patients and clinical practice is a necessary requirement
before being able to assess the impact of this GC on
clinical outcomes.
Stochastic TARgeted (STAR) is a clinically model-
based GC protocol on a clinically validated physiological
model,16,17 which provides patient-speciﬁc recommenda-
tions for insulin and nutrition. It controls hyperglycemia
and manages a maximum of 5% risk of mild
hypoglycemia18,19 while using a larger target range.
Since 2010, two hospitals have been using STAR protocol
with 4.4–8.0 mmol/L target range as a standard of care for
ICU GC, namely the Christchurch Hospital, New Zealand,
and Kálmán Pándy Gyulá Hospital, Hungary. Stewart et
al,15 have tested the performance, safety,and generality of
this protocol in these two ICUs. However, its generality
hasn’t been tested in a different background, such as
Malaysia, which has an ethnically very different cohort
with different clinical practice.
This paper presents the results and analysis of the
STAR pilot trial in the International Islamic University
Malaysia Medical Centre (IIUMMC) ICU. An internal
study by fellow Malaysian collaborators indicates that
50% of Malaysian ICUs have the tendency to use a 6.0–
10.0 mmol/L target range, and this is the same target range
that is used in the IIUMMC using a sliding scale control.
The main goal of this pilot trial is to assess performance,
safety, and implementation issues on STAR using this
target range. Speciﬁcally, the following areas of STAR
protocol control were explored and presented in the fol-
lowing sections: i) Exploration of clinical GC performance
and safety; and ii) Overview of treatment preference to
reduce workload.
Methods and materials
STAR protocol
To optimize safety and performance, STAR uses a model-
based time varying patient-speciﬁc insulin sensitivity (SI)
to capture development in patient physiological condition,
inter- and intra-patient ﬂuctuation, and insulin-nutrition
metabolism over time. Further details can be found in
Lin et al,17 but, in short, the metabolic model uses
accounts for endogenous secretion and clearance of glu-
cose and insulin from blood and interstitial ﬂuid compart-
ments, as well as the appearance of exogenous insulin and
nutrition.
Starting criteria was two blood glucose (BG) measure-
ments over 10 mmol/L within a 1-hour period or any
speciﬁc attending clinician choice. The default and bench-
marked BG target range of STAR is 4.4–8.0 mmol/L (80–
145 mg/dL) based on reduced risks with increased BG in
intermediate bands.20 STAR is implemented in a tablet
computer to provide an automated and specialized user
interface into which nutrition and insulin information can
be recorded and recommended. Nutrition in ICU patients
is administered via enteral, total parenteral, or a combina-
tion of both routes.
Once a BG measurement has been taken and recorded,
hour-to-hour insulin sensitivity (SI) is identiﬁed,21 and sto-
chastic forecasting is used to determine likely future out-
comes in insulin sensitivity for the next 1–3 hours. Likely
BG outcomes are then computed, in particular, the 5th, 50th
and 95th percentiles, allowing central tendencies and possi-
ble risks of extremes in BG to be evaluated. The insulin-
nutrition combination for 1–3 hours intervention that best
overlaps the resulting BG within a target range is selected
and recommended by placing the 5th percentile BG outcome
on the lower edge of the clinically speciﬁed target range.
STAR seeks to maximize nutrition delivery, while dosing
insulin in this context. If, for maximum nutritional and insu-
lin treatments, the BG outcome range does not sufﬁciently
overlap the clinical target range, then STAR will recommend
a drop in nutrition to maintain GC and reduce risk.19 The
nutrition will be raised back to its daily target based on total
energy requirements, as soon as possible. In cases where the
nutrition must be clinically determined or switched off,
STAR can be set to give insulin recommendations only.
Nutrition control in the IIUMMC ICU is done separately
from STAR, but the given values are communicated directly to
the STAR tablet. The guideline recommends a target energy
intake of 25 kcal/kg/day and at least 1.2–1.5 g/kg/day of
protein. For obese patients, 120% of Ideal Body Weight
(IBW) or Actual Body Weight (ABW) times 0.25+IBW is
used as a suggestion guideline (or use ABW for underweight
patients). Energy intake should be adjusted according to the
severity and type of illness while avoiding overfeeding.
Abu-Samah et al Dovepress
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When clinical opinion has determined that a patient is
stable and insulin treatment should end or more than 5 hours
has elapsed between treatment, STAR should be stopped. If
insulin treatment is required again later, the patient is restarted
and classiﬁed under a new episode. Additionally, in this ICU,
the stopping criteria were when the BG is within the target
range at insulin of 0.5U/hour for 2 hours. Figure 1 summarizes
the STAR work and GC logic.
The default target range can be changed based on clin-
ical team consultation. In this study, the target range was
increased to 6.0–10.0 mmol/L (106–180 mg/dL) following
the standard care range in IIUMMC ICU. Hyperglycemia
has been deﬁned as a blood glucose level higher than 10.0
mmol/l, but this BG level is not considered as alarming in
the Malaysian ICU. Insulin was delivered as infusion with
0.5 U/hour increment with a maximum dose of 8 U/hour.
BG measurements were made using B-Braun glucometers
(Melungen, Germany). STAR then identiﬁes a new insulin
rate, which was then given by the nurse. The time interval
until the next BG measurement is also selected by the
medical staff based on available 1–3 hourly treatment
recommendations.
Pilot trial patients
By default, all patients satisfying the inclusion criteria
along with their agreement were included in this pilot
trial. A few patients clinically determined to be treated
using insulin bolus instead of infusion were, however,
excluded. In this trial for Malaysian critically ill patients,
269 episodes of insulin infusion treatment under STAR
(totaling 11,127 hours) from 88 patients were extracted.
All data are from January 2017 to mid-September 2018,
and all patients, except one Indian (episode 59a) were of
Malay ethnicity. All of the patients were treated using the
hospital’s standard target range of 6.0–10.0 mmol/L.
One hundred and twenty-seven “small” episodes were
eliminated because they had less than 20 hours of control
using STAR. These were removed to avoid bias in the analysis
as the time taken to reduce BG into the target range is pro-
portionally larger. This study was ﬁnally executed using 142
episodes, from 81 patients (9,587 hours). Twenty-eight
patients had more than one insulin treatment episode on
STAR due to recurrent hyperglycemia. Their per-episode
data are labeled with a number for patient identiﬁcation and
a letter for episode. The patients included in the study had a
New patient episode
Stop Patient data and current BG, insulin and nutrition
STAR interface
Is this the first
BG measure?Is patient stable?
Record BG measure
+Insulin
+Nutrition
Measurement interval
Give treatment based on
STAR’s proposition
Choose insulin and/or nutrition
treatment dose
Forecast likely changes in Si
STAR Calculations
95thB
G
S
I
50th
5th
Time
95th
50th
5th
Time
Target band
tn tn
Continue with standard insulin
dose until 2 BG measures are
available
Fit insulin sensitivity (SI) over
last measurement interval
No
Yes No
Yes
Figure 1 Summary of the STAR protocol. Grey blocks refer to actions taken at patient bedside.
Abbreviations: BG, blood glucose; STAR, Stochastic TARgeted.
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prevalence of males. The Ethics Committee of IIUMMC
granted approval for this trial and the audit, analysis, and
publication of these data. The IIUM Research Ethics
Committee (IREC) operates in accordance with the
Declaration of Helsinski, International Conference of
Harmonization Good Clinical Practice Guidelines (ICH-
GCP), Malaysia Good Clinical Practice Guidelines, and
Council for International Organizations of Medical Sciences
(CIOMS) International Ethical Guidelines. Figure 2 sums the
patient/episode selection process.
Control performance, safety, and
compliance
The safety and performance of STAR were assessed using
the following deﬁnitions:
● Performance:
○ Number of BG measurements in different BG
bands and the normoglycemia, 4.0–10.0 mmol/L
(72–180 mg/dL) band.
○ Number of hyperglycemic incidents (BG measure-
ment >10 mmol/L).
● Safety:
○ Number of severe hypoglycemic incidents (BG
measurement <2.2 mmol/L).22
○ Number of mild hypoglycemic incidents (BG mea-
surement <4.0 mmol/L).14
Due to irregular sampling intervals, per-patient epi-
sode BG data were analyzed and used after linear inter-
polation at hourly intervals. The interpolation is done on
the BG measurements to ﬁll the BG values when the
options of 2-hourly and 3-hourly treatment were selected.
This choice ensures a fair comparison between different
protocols, and linear interpolation has been shown to be
the optimal choice.23 Statistical assessment was done
using standard metrics, as proposed by Finfer et al24.
1. Measures of central tendency and dispersion: The
mean, median, and inter-quartile range (IQR) per
patient (or per episode).
2. Range and exposure measures: The percentage of
time the measurement is in the target range and the
percentage of time the measurement is outside a
nominated target range.
Additionally, preference of treatment from STAR was
assessed in this study focusing on the chosen treatments
and available 1–3 hourly recommendations. The number
of times a treatment was chosen is calculated to see the
tendency to introduce less workload and the trust on auto-
mated recommendations.
Results
BG control performance and safety
The clinical results are presented in Table 1. A totla of 7,012
measurements were taken within 9,587 hours, with an average
measurement interval of 1.37 hours. Interpolation of BG mea-
surement resulted in 9,654 measurements; 39.6% of BG was
within 4.4–8.0 mmol/L, and 60.7% was within the 6.0–10.0
mmol/L target range. The cohort’s BG median value was 8.5
mmol/L. The percentage of BG >10.0 mmol/L was 28.4%.
There were 100 mild hypoglycemia (in 42 episodes) and six
severe hypoglycemia (in ﬁve episodes) incidences. The med-
ian and IQR nutrition rates reported in Table 1 are based on the
recorded STAR nutrition rates by clinical staff based on their
nutrition control recorded in the tablet. All hypoglycemia and
hyperglycemia incidences were manually veriﬁed. Figure 3
illustrates per-episode BG measurements, episode 1a to 81a
from left to right in a boxplot representation.
An example of individual patient episode results can be
referred to in Figure 4. Thisshows the time course for BG
(measurement and model ﬁt), insulin (plasma, interstitial and
infused), nutrition (enteral and parenteral nutrition), and SI in
episode 38a. This episode has one severe hypoglycemia
88 Patients on STAR glucose
control
81 patients analysed 142 episodes analysed
(53 Male : 28 Female)
269 episodes data received
127 episodes removed
as # hours < 20
Figure 2 Summary of the cohort data and its selection for analysis.
Abbreviations: STAR, Stochastic TARgeted.
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incidence at t=31.5 hours due to stoppage of enteral nutrition.
Per-episode BG Cumulative Distributive Functions (CDFs)
are shown in Figure 5. The whole cohort median is shown as
a dashed line, while the 25–75% range is presented as a dark
blue interval and 5–95% is in the light blue interval. Even
though many of the BG measurements were outside of the
target control, most of the patients BG levels were within the
25th and 75th percentile of the whole cohort’s BG median.
Table 1 Cohort and per-patient glycemic control results
Performance and safety statistics STAR: 6.0–10.0 mmol/L
Normal Interpolated
Number of episodes 142
Number of BG measurements 7,012
Total hours 9,587 9,654
Median hours on protocol 49 (34–80)
Median days on protocol 2.0 (1.4–3.3)
Average measurement interval 1/1.37 hours 1/1.38 hours
Insulin rate (U/h): Median (IQR) 1.6 (0.4–3.4)
Max Insulin rate (U/h): Median (IQR) 8.0 (6.9–8.9)
Dextrose rate (g/h): Median (IQR)] 5.2 (2.8–7.0)
Intervention of insulin in the control (%) 80.12
Median (IQR) BG (mmol/L)
Whole cohort 8.8 8.5
Per patient 8.2 (7.4–9.5) 8.15 (7.4–9.5])
Median time to BG <10 (hours) 2.8 (1.8–4.0)
% BG >10
Whole cohort 34.1 28.4
Per patient 25.8 (16.1–40.0) 21.0 (11.4–36.1)
% BG within 6.0–10.0 mmol/L
Whole cohort 52.6 60.7
Per patient 54.4 (44.4–62.2) 61.9 (51.2–71.9)
% BG within 4.4–8.0 mmol/L
Whole cohort 37.3 39.6
Per patient 41.8 (27.3–57.1) 44.2 (25.0–61.4)
% BG <4.0 mmol/L
Whole cohort 1.43 0.78
Per patient 0.0 (0.0–2.2) 0.0 (0.0–0.0)
# Incidences with BG <4.0 mmol/L 100
# Episodes with BG <4.0 mmol/L 42
% BG <2.2 mmol/L
Whole cohort 0.07 0.02
Per patient 0.0 (0.0–0.0) 0.0 (0.0–0.0)
# Incidences with BG <2.2 mmol/L 6
# Episodes with BG <2.2 mmol/L 5
Abbreviations: BG, blood glucose; IQR, interquartile range; STAR, Stochastic TARgeted.
Dovepress Abu-Samah et al
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Per-patient box-plot
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Figure 3 Per-patient boxplots of BG measurements.
Abbreviation: BG, blood glucose.
Figure 4 Episode 38a.
Abbreviations: I, plasma insulin; Q, interstitial insulin; SI, insulin sensitivity; BG, blood glucose; EN, enteral nutrition; PN, perenteral nutrition.
Figure 5 Per-episode BG CDFs deﬁned on whole cohort.
Abbreviations: BG, blood glucose; CDFs, cumulative distributive functions.
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BG treatment preference
Table 2 shows the number of 1–3 hourly recommended treat-
ments. It also shows the number of chosen treatment when
each type of the treatment were available; 68.7% of 2-hourly
and 78.5% of 3-hourly options were selected when these were
available with the 1-hourly and 1 plus 2-hourly options. This
shows that, when 2- and 3-hourly options were available,
clinical staff chose the option than could reduce workload.
These options were, however, only chosen for 26.3% of the
total treatment. The total number of available treatments is
equal to the total number of 1-hourly available treatment,
8,359, and the 2- and 3 -hourly options were chosen only
2,202 times. The majority of cases were still treated within a
1 hour interval.
Discussion
The objective of this pilot trial is to look at the performance,
safety, and treatment preference for STAR protocol
implementation in a Malaysian ICU. This trial used a 6.0–
10.0 mmol/L target range to suit the practice in respective
IIUMMC ICUs. The clinical assessments resulted in a correct
performance, 60.7% in the target range and 70.84% in the
normoglycemia, 4.0–10.0 mmol/L range. The percentage of
BGmeasurements higher than 10 mmol/L was 28.4%, but this
can be attributed to the starting BGs, which were relatively
high (cf. the histogram of starting BG frequencies in Figure 6).
Nevertheless, STAR have a median time to BG <10.0 mmol/L
of 2.8 (1.8–4.0) hours only, indicating its fast acting control to
bring patient BG to the target range. Note that 10 episodes
were started with BG less than 10 mmol/L (cf. Figure 6),
indicating the exceptional cases decided by attending clini-
cians. In term of safety, only 0.78% of cohort measurements
were below 4.0 mmol/L, which is less than 5%, as promised
by STAR. However, individually 14 episodes had more than
5% of mild hypoglycemia, the limit set in the control, which
deserves further individual diagnosis. Five episodes were
Table 2 1–3 hourly treatment chosen for each episode
Type of BG treatment Number of available BG treatment
1-hourly 8,359
2-hourly 2,441
3-hourly 1,516
Number of chosen/available BG treatment
Context 1-hourly 2-hourly 3-hourly
Only 1-hourly available 186/186 (100%)
Only 1 and 2-hourly available 529/608 (87.0%) 79/115 (68.7%)
All three options available 5,442/7,565 (71.9%) 933/2,326 (40.1%) 1,190/1,516 (78.5%)
Total and overall % 6,157/8,359 (73.7%) 1,012/8,359 (12.1%) 1,190/8,359 (14.2%)
Abbreviation: BG, blood glucose.
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Figure 6 Histogram for starting blood glucose level.
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diagnosed with severe hypoglycemia, their individual results
are further elaborated in Table S1 in the Supplementery mate-
rials with potential diagnoses.
To compare the performance of the IIUMMC STAR
trial with results from Christchurch and Gyulá as reported
in Stewart et al,15 a cohort with a minimum 10 hours of
measurement was studied and the comparison is presented
in Table 3. Additional episodes were added to the initial
cohorts which presented with a 20 hours measurement
minimum. For this cohort, a median of 61.5% of time,
the cohort’s BG is within their target range. This number is
relatively low as compared to the 86.6 (75.0–94.1)%
(Christchurch) and 87.1 (79.3–91.1)% (Gyulá) in the
4.4–8.0 mmol/L target range. Furthermore, a staggering
28.4% of the measurements are hyperglycemic, as com-
pared to 4.4% and 3.0% in Christchurch and Gyulá,
respectively. A revision of the target range for Malaysian
patients is proposed to lower the number of hyperglycemic
incidences while maintaining the performance and safety.
Second, the results also question the accuracy of predic-
tion from the stochastic model,16 which was developed
using the Christchurch patient population with potentially
very different SI proﬁles. The SI proﬁles of the IIUMMC
cohort can be referred to in Figure S1, where the majority
of patients have very low SI, and lower than the
Christchurch patients.13
In light of ﬂexibility of work reduction, between 2-hourly
and 3-hourly options when they were available, clinical deci-
sions tended to go for the longer option. This tendency showed
the faith in the protocol recommendations. However, in terms
of general workload, these choices only contributed to 26.3%
of overall treatment, and 73.7% were of 1-hourly treatments.
The averagemeasurement per day is 18.1, as compared to 13.6
and 11.7 in Christchurch and Gyulá, respectively. The results
show that most patients were offered with single choice treat-
ment, the 1-hourly and this can be attributed to the generally
low SI patient. For example, episode 63a has 618 BG mea-
surements with a median SI of 1.1E10-4 (Lower than the
cohort’s median of 1.97E10-4), 82.1% of the time was treated
with 1-hourly options.
A comparison of performance towards the nutrition
intervention cannot be done as the IIUMMC pilot trial is
an insulin only control, and recorded dextrose does not
100% represent the real nutrition delivery in the hospi-
tal. This leads to the question of whether a better per-
formance can be achieved if the GC control is paired
with STAR-based nutrition control.25 The median (IQR)
insulin (U/h) rate is 1.5 (1.0–2.0). Statistically, this
value is the lowest and closer to Christchurch as com-
pared to Gyulá, as is the APACHE II score between the
three cohorts. Less severity of illness factor contributes
to the overall insulin intervention, despite the low SI.
Figure 7 illustrates the percentage of time insulin is
given with speciﬁc rates resulting to insulin intervention
of 66.3%, with only 3.1% of higher insulin administra-
tion with advice from intensivists. A revision of the
target range can have an impact on the value of insulin
administered. However, at this point of analysis, no
conclusion can be made whether a smaller/lower target
range results in lower insulin or not.
Table 3 Per-episode hourly interpolated glycemic control results for the three STAR cohorts in IIUMMC, Christchurch and Gyulá
Hospital ICUs
Statistics STAR trial Christchurch Gyulá IIUMMC
Starting criteria 2 successive BG measurements over 8
mmol/L within a 4-h period
2 successive BG measurements over 10 mmol/L within a 1-h period
Number of episodes 267 47 209
Measurements per day 13.6 11.7 18.1
APACHE ll score 21.0 (16.0–25.0) 32 (28.0–36.0) 16 (11.8–23.0)
% time 4.4–8.0 mmol/L 86.6 (75.0–94.1) 87.1 (79.3–91.1) 46.2 (25.5–63.6)
% time 6.0–10.0 mmol/L No information 61.5 (50.0–73.5)
% time >10.0 mmol/L 4.4 3.0 28.4
% time <4.0 mmol/L 0.6 0.9 0.8
Median insulin rate 2.7 (1.9–3.5) 3.2 (2.4–4.6) 1.5 (1.0–2.0)
Notes:APACHE ll is one of the scoring system in the ICU to classify overall per-patient severity-of-disease. It is applied within 24 hours of admission of a patient to an intensive care
unit (ICU). An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death.
Abbreviations: ICU, intensive care unit; IIUMMC, International Islamic University Malaysia Medical Centre; STAR, Stochastic TARgeted.
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Conclusions
This pilot clinical trial is the ﬁrst attempt to use the STAR
protocol in a Malaysian ICU. The main objective is to test its
implementation performance, safety, and trust on the ﬂexible
1–3 hourly treatment. The trial was performed using
Malaysia standard, but a higher target range, as IIUMMC
staff were more comfortable with it. Results show that STAR
is adaptable with the higher target range and provided correct
performance and safety. STAR promises a lower workload
with the 1–3 hourly treatment options, and the trial proves the
staff preference and trust in the 2- and 3-hourly recommen-
dations when available. However, the expected performance
in the target range is still considered low as the expectant is
towards >85% with lower hyperglycemia measurements.
Furthermore, STAR in most cases offered only 1-hourly
treatment. The provided analysis justiﬁes improvement for
STAR protocol parameters such as its prediction model to
consider a multi-center population, especially for patients
with very low SI. Second, with or without prediction model
improvement, a study on the optimized target range shall be
done to consider such a clinical environment.
Abbreviations list
ABW, actual body weight; BG, blood glucose; CDF,
cumulative density function; DM, diabetes mellitus; EN,
enteral nutrition; GC, glycemic control; IBW, ideal body
weight; ICU, intensive care unit; IQR, interquartile range;
SI, insulin sensitivity; STAR, Stochastic TARgeted.
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Figure S1 Per-episode insulin sensitivity (SI) proﬁles for the pilot trial cohort.
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